Abstract P1063: Association of Demographic and Clinical Factors with SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

R Ryan Demmer (Mayo Clinic, Rochester, Minnesota, United States) C Chaoqi Wu (Columbia University, New York City, New York, United States) J John Kim Y Yifei Sun (State Key Laboratory of Green Pesticide, Engineering Research Center of Photoenergy Utilization for Pollution Control and Carbon Reduction, Ministry of Education, College of Chemistry) P Pallavi Balte M Mary Cushman R Rebekah Boyle (University of Vermont, Burlington, Vermont, United States) R Russell Tracy L Linda Styer (New York State Department of Health, Albany, New York, United States) T Taison Bell (UVA Health, Charlottesville, Virginia, United States) M Michaela Anderson (University of Pennsylvania, Philadelphia, Pennsylvania, United States) N Norrina Allen (NORTHWESTERN UNIVERSITY, Chicago, Illinois, United States) P Pamela Schreiner (UNIV MINNESOTA, Minneapolis, Minnesota, United States) R Russell Bowler D David Schwartz (University of Colorado, Aurora, Colorado, United States) J Joyce Lee (Bionano Genomics Inc) V Vanessa Xanthakis J Jean Rock (New York State Department of Health, Albany, New York, United States) R Rachel Bievenue A Amber Pirzada M Margaret Doyle (University of Vermont, Burlington, Vermont, United States) E Elizabeth Regan (National Jewish Health, Denver, CO, USA.) B Barry Make (Johns Hopkins University, Baltimore, MD, USA.) A Alka Kanaya (UCSF, San Francisco, California, United States) N Namratha Kandula (Northwestern University, Chicago, Illinois, United States) S S Morganroth (University of Pittsburgh, Pittsburgh, Pennsylvania, United States) J Joe Coresh (New York University Grossman School of Medicine, New York, New York, United States) C Carmen Isasi (Albert Einstein College of Medicine, Bronx, New York, United States) L Laura Raffield M Mitchell Elkind (American Heart Association, Dallas, Texas, United States) V Virginia Howard (University of Alabama at Birmingham, Birmingham, Alabama, United States) V Victor Ortega (Mayo Clinic, Carefree, Arizona, United States) P Prescott Woodruff S Shelley Cole (Texas Biomedical Research Institute, San Antonio, Texas, United States) J Joel Henderson N Nicholas Mantis (New York State Department of Health, Albany, New York, United States) E Elizabeth Oelsner (Columbia University, New York, New York, United States)

Abstract

Background: Despite the availability of effective vaccines and a recent decrease in annual deaths, coronavirus disease-2019 (COVID-19) remains a leading cause of death. Serological studies of anti-nucleocapsid (N) antibody response to infection provide insights into host immunobiology of adaptive immune response, which holds promise for identifying high-risk individuals for adverse acute and chronic COVID-19 outcomes. Hypothesis: Among participants previously infected with SARS-CoV-2, traditional vascular disease risk factors are associated with higher anti-N antibodies while vaccination is associated with lower anti-N antibodies. Methods: Among previously infected participants, anti-N antibodies were measured from dried blood spots collected between February 2021-February 2023 among 1,419 Collaborative Cohort of Cohorts for COVID-19 Research (C4R) participants with prior SARS-CoV-2 infection. We measured anti-N IgG antibodies reported as median fluorescence intensity (MFI) units; reactivity (i.e., seropositivity) was defined based on MFI above a validated threshold. Vascular disease risk factors were assessed via pre-pandemic in-person examination, questionnaires, and medical record review. Multivariable generalized linear models regressed anti-N reactivity (modified Poisson) or LN transformed MFI (linear). Results: Among 1,419 participants with prior infection, mean age (standard deviation) was 65.8(12.1) years, 61% were women, and 42.8% were self-reported from a race/ethnicity minority group. Participant reactivity to nucleocapsid peaked at 69% by 4 months post-infection and waned to only 44% ≥12 months after infection. After multivariable adjustment, higher anti-N antibody response was associated with older age, Hispanic (vs. White) or American Indian (vs. White) race/ethnicity, lower income and education, former smoking, and higher anti-spike antibody levels. Asian race (vs. White) and vaccination ( even after infection ) were associated with lower nucleocapsid reactivity; common cardiometabolic co-morbidities were not associated with anti-N reactivity or levels (Figures 1 and 2). Conclusions: Among participants previously infected with SARS-CoV-2, select sociodemographic and behavioral risk factors were associated with higher anti-N antibody levels while vaccination was associated with lower anti-N antibody levels. The observation that vaccination, even after infection, is related to lower anti-N antibody levels merits further investigation.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (37)

R

Ryan Demmer

Mayo Clinic, Rochester, Minnesota, United States

C

Chaoqi Wu

Columbia University, New York City, New York, United States

J

John Kim

Y

Yifei Sun

State Key Laboratory of Green Pesticide, Engineering Research Center of Photoenergy Utilization for Pollution Control and Carbon Reduction, Ministry of Education, College of Chemistry

P

Pallavi Balte

M

Mary Cushman

R

Rebekah Boyle

University of Vermont, Burlington, Vermont, United States

R

Russell Tracy

L

Linda Styer

New York State Department of Health, Albany, New York, United States

T

Taison Bell

UVA Health, Charlottesville, Virginia, United States

M

Michaela Anderson

University of Pennsylvania, Philadelphia, Pennsylvania, United States

N

Norrina Allen

NORTHWESTERN UNIVERSITY, Chicago, Illinois, United States

P

Pamela Schreiner

UNIV MINNESOTA, Minneapolis, Minnesota, United States

R

Russell Bowler

D

David Schwartz

University of Colorado, Aurora, Colorado, United States

J

Joyce Lee

Bionano Genomics Inc

V

Vanessa Xanthakis

J

Jean Rock

New York State Department of Health, Albany, New York, United States

R

Rachel Bievenue

A

Amber Pirzada

M

Margaret Doyle

University of Vermont, Burlington, Vermont, United States

E

Elizabeth Regan

National Jewish Health, Denver, CO, USA.

B

Barry Make

Johns Hopkins University, Baltimore, MD, USA.

A

Alka Kanaya

UCSF, San Francisco, California, United States

N

Namratha Kandula

Northwestern University, Chicago, Illinois, United States

S

S Morganroth

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

J

Joe Coresh

New York University Grossman School of Medicine, New York, New York, United States

C

Carmen Isasi

Albert Einstein College of Medicine, Bronx, New York, United States

L

Laura Raffield

M

Mitchell Elkind

American Heart Association, Dallas, Texas, United States

V

Virginia Howard

University of Alabama at Birmingham, Birmingham, Alabama, United States

V

Victor Ortega

Mayo Clinic, Carefree, Arizona, United States

P

Prescott Woodruff

S

Shelley Cole

Texas Biomedical Research Institute, San Antonio, Texas, United States

J

Joel Henderson

N

Nicholas Mantis

New York State Department of Health, Albany, New York, United States

E

Elizabeth Oelsner

Columbia University, New York, New York, United States